Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

The conversation provides a detailed list of blood tests recommended before starting finasteride to establish a baseline for monitoring potential side effects. A shorter list is also provided for those with limited funds, and the user shares personal experience of using finasteride without issues for about nine years.

The conversation is about whether the Ordinary's Multi-Peptide Serum for hair density can be mixed with finasteride. A video was mentioned that shows the serum being mixed with Stemoxydine.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.

Many users adjust finasteride dosage due to varying side effects and efficacy, with some finding lower doses effective while others experience better results at higher doses. The discussion highlights the complexity of DHT levels, individual sensitivity, and the potential impact on hair loss treatment outcomes.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

A user discusses their hormone blood test results before starting finasteride for hair loss, noting high DHT and estradiol levels. They tried topical finasteride for a few days but felt tired.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

The conversation discusses the fluctuation of testosterone levels in men under 40 and the difference between serum DHT and scalp DHT. It also mentions that DHT levels are higher on Dutasteride than on Finasteride, which is unusual.

The Ordinary multipeptide hair serum is used alongside treatments like minoxidil, topical finasteride, and derma rolling, with some users reporting hair thickening and vellus hair regrowth. However, experiences vary, and some users are skeptical due to the lack of solid evidence and mixed efficacy reports.

The conversation discusses the pros and cons of using propylene glycol versus ethyl alcohol in topical solutions for finasteride and minoxidil. It questions why propylene glycol is commonly used and whether ethyl alcohol might be a better option.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

A 23-year-old male switched to a topical solution containing Fin 0.1% and Min 5% from a previous solution with Fin 1% and Min 5%, noticing increased hair shedding. He is concerned about losing around 50 hairs while using ketoconazole shampoo.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation discusses concerns about potential side effects, specifically gynecomastia, from taking 1mg of finasteride every other day for hair loss. Bloodwork results were shared, but more information was requested to provide advice.

A man shared his 6-month hair regrowth progress using 0.5mg of finasteride daily and recently increased the dose to 1mg. Users discussed the effectiveness of the treatment and shared their own experiences with hair loss treatments.

A user experienced libido issues after using finasteride for five months, with elevated prolactin and estradiol levels. The discussion includes differing opinions on whether these symptoms are due to hormonal imbalances or post-finasteride syndrome.

A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

Someone is selling 90g of RU58841 with 99.14% purity from Lyphar Biotech at a reduced price. A user questions the seller's motives, suggesting possible side effects.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.